Quarterly report pursuant to Section 13 or 15(d)

Condensed Balance Sheets

v2.4.0.6
Condensed Balance Sheets (USD $)
In Thousands, unless otherwise specified
Jun. 30, 2012
Dec. 31, 2011
Current assets:    
Cash $ 4,104 $ 5,406
Receivables 3,910 3,720
Prepaid expenses and other current assets 805 836
Total current assets 8,819 9,962
Property and equipment, net 1,235 255
Total assets 10,054 10,217
Current liabilities:    
Accounts payable 5,405 4,789
Accrued clinical trials expenses 600 161
Other accrued liabilities 497 173
Warrant liability, current 462 0
Current portion of long-term debt, net of discount 2,500 0
Total current liabilities 9,464 5,123
Warrant liabilities 4,073 3,611
Royalty liability 9,849 9,309
Long-term debt, net of discount 9,663 12,253
Total liabilities 33,049 30,296
Commitments and contingencies      
Stockholders' deficit:    
Common stock, at amounts paid-in 258,539 256,436
Additional paid-in capital 20,301 18,433
Accumulated deficit (301,835) (294,948)
Total stockholders' deficit (22,995) (20,079)
Total liabilities and stockholders' deficit $ 10,054 $ 10,217